Artificial intelligence (AI) oncology firm, Massive Bio has teamed with the New York-based Mika Health to bring the latter’s oncology digital therapeutic to more patients in a bid to expand patient access to psycho-oncology services, biomarker testing and clinical trials.

The partnership will see patients provided with free access to Mika Health’s software designed to address oncology-specific fatigue, anxiety and depression as well as expanding access to ‘right on-market’ or investigative treatment and testing through Massive Bio’s own platform.

Additionally, the two-way partnership means that patients receiving treatment on Mika’s personalised oncology digital therapeutic app will have the ability to opt into Massive Bio’s AI-enabled clinical trial matching and biomarker testing eligibility engine. At the same time, Massive Bio says that it plans to hand out the Mika Health app to its registry of hundreds of thousands of patients.

Dr Selin Kurnaz, CEO of Massive Bio, said: “Our partnership marks a significant leap towards global personalised cancer care at a time when too many patients are struggling to find effective treatments. By combining our AI expertise with Mika Health’s comprehensive digital therapy, we can significantly enhance cancer patient outcomes and experiences with expanded access to innovative therapies and direly needed patient support. This collaboration not only addresses the immediate needs of patients but also bridges critical gaps in mental and physical health care during their treatment journey.”

A report published by GlobalData details how in 2020 the overall market for telehealth apps stood at around $2bn, but in 2024 the figure is estimated to rise to $5bn, with further growth projected into 2030 where it’s estimated to hit $12bn dollars. At the same time, the competitively smaller market of remote patient monitoring sat at a value of around $600m, with that value estimated to rise to $760m by 2030.

Mark Slaughter, chief strategy officer of Mika Health, added, “As cancer treatments become more sophisticated and personalised, patients are increasingly unable to identify and access the targeted therapy and psycho-oncological support they need. By combining forces with Massive Bio, Mika Health aims to close the access gap, raise the pervasiveness of standard of care quality, and accelerate time to the right treatment for patients.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Elsewhere in the field of oncology applications, the UK-based pharmaceutical supply company, Sciensus, has announced that it has acquired the cancer patient support app, Vinehealth.